BBV154

BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19

Key Attributes:

  • An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
  • Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.
Intranasal covid-19 vaccine

  • The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.
  • Non-invasive, Needle-free.
  • Ease of administration – does not require trained health care workers.
  • Elimination of needle-associated risks (injuries and infections).
  • High compliance (Ideally suits for children’s and adults).
  • Scalable manufacturing – able to meet global demand.

covid-19 vaccine

Protective Efficacy of candidate vaccine ChAd-SARS-CoV-2-S demonstrated in Mice and Hamsters:

Mice and Hamsters immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against SARS-CoV-2 challenge, more so than one or two intramuscular immunizations of the same vaccine and dose. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways.

Thus, intranasal immunization of ChAd-SARS-CoV-2-S can create an immune response in the nose, which is the point of entry for the virus—thereby protecting against disease, infection, and transmission.

For more information on the study: https://www.biorxiv.org/content/10.1101/2020.12.02.408823v1

*Disclaimer: The provided study information is a preprint publish and has not yet undergone peer review. The findings are provisional, and the conclusions/final results may differ.

Forward-Looking Statement: [Download PDF]